Literature DB >> 26135114

Quantification of Dynamic 11C-Phenytoin PET Studies.

Syahir Mansor1, Ronald Boellaard2, Femke E Froklage3, Esther D M Bakker2, Maqsood Yaqub2, Rob A Voskuyl3, Lothar A Schwarte4, Joost Verbeek2, Albert D Windhorst2, Adriaan Lammertsma2.   

Abstract

UNLABELLED: The overexpression of P-glycoprotein (Pgp) is thought to be an important mechanism of pharmacoresistance in epilepsy. Recently, (11)C-phenytoin has been evaluated preclinically as a tracer for Pgp. The aim of the present study was to assess the optimal plasma kinetic model for quantification of (11)C-phenytoin studies in humans.
METHODS: Dynamic (11)C-phenytoin PET scans of 6 healthy volunteers with arterial sampling were acquired twice on the same day and analyzed using single- and 2-tissue-compartment models with and without a blood volume parameter. Global and regional test-retest (TRT) variability was determined for both plasma to tissue rate constant (K1) and volume of distribution (VT).
RESULTS: According to the Akaike information criterion, the reversible single-tissue-compartment model with blood volume parameter was the preferred plasma input model. Mean TRT variability ranged from 1.5% to 16.9% for K1 and from 0.5% to 5.8% for VT. Larger volumes of interest showed better repeatabilities than smaller regions. A 45-min scan provided essentially the same K1 and VT values as a 60-min scan.
CONCLUSION: A reversible single-tissue-compartment model with blood volume seems to be a good candidate model for quantification of dynamic (11)C-phenytoin studies. Scan duration may be reduced to 45 min without notable loss of accuracy and precision of both K1 and VT, although this still needs to be confirmed under pathologic conditions.
© 2015 by the Society of Nuclear Medicine and Molecular Imaging, Inc.

Entities:  

Keywords:  11C-phenytoin; PET quantification; kinetic modeling; test–retest variability

Mesh:

Substances:

Year:  2015        PMID: 26135114     DOI: 10.2967/jnumed.115.158055

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  4 in total

1.  (18)F-FCWAY, a serotonin 1A receptor radioligand, is a substrate for efflux transport at the human blood-brain barrier.

Authors:  Jeih-San Liow; Sami S Zoghbi; Shuo Hu; Matthew D Hall; Christina S Hines; H Umesha Shetty; Maria D Araneta; Emily M Page; Victor W Pike; William C Kreisl; Peter Herscovitch; Michael M Gottesman; William H Theodore; Robert B Innis
Journal:  Neuroimage       Date:  2016-05-19       Impact factor: 6.556

2.  Impact of P-Glycoprotein Function on the Brain Kinetics of the Weak Substrate 11C-Metoclopramide Assessed with PET Imaging in Humans.

Authors:  Nicolas Tournier; Martin Bauer; Verena Pichler; Lukas Nics; Eva-Maria Klebermass; Karsten Bamminger; Peter Matzneller; Maria Weber; Rudolf Karch; Fabien Caillé; Sylvain Auvity; Solène Marie; Walter Jäger; Wolfgang Wadsak; Marcus Hacker; Markus Zeitlinger; Oliver Langer
Journal:  J Nucl Med       Date:  2019-01-10       Impact factor: 11.082

3.  Model selection criteria for dynamic brain PET studies.

Authors:  Sandeep S V Golla; Sofie M Adriaanse; Maqsood Yaqub; Albert D Windhorst; Adriaan A Lammertsma; Bart N M van Berckel; Ronald Boellaard
Journal:  EJNMMI Phys       Date:  2017-12-06

4.  Test-Retest Repeatability of [18F]MC225-PET in Rodents: A Tracer for Imaging of P-gp Function.

Authors:  Lara García-Varela; David Vállez García; Manuel Rodríguez-Pérez; Aren van Waarde; Jürgen W A Sijbesma; Anna Schildt; Chantal Kwizera; Pablo Aguiar; Tomás Sobrino; Rudi A J O Dierckx; Philip H Elsinga; Gert Luurtsema
Journal:  ACS Chem Neurosci       Date:  2020-02-03       Impact factor: 4.418

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.